Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 5.85M | 12.13M | ― | 6.10M | 5.23M |
Gross Profit | 4.08M | 9.32M | -20.63M | 4.38M | -3.28M |
EBITDA | -66.61M | -38.86M | -33.28M | -43.26M | -12.04M |
Net Income | -74.82M | -46.25M | -38.08M | -51.86M | -18.08M |
Balance Sheet | |||||
Total Assets | 226.10M | 263.34M | 189.59M | 302.98M | 202.86M |
Cash, Cash Equivalents and Short-Term Investments | 42.56M | 78.63M | 73.93M | 142.74M | 136.66M |
Total Debt | 70.42M | 68.22M | 31.34M | 42.31M | 20.01M |
Total Liabilities | 88.51M | 83.74M | 38.20M | 51.85M | 24.68M |
Stockholders Equity | 137.59M | 183.94M | 151.39M | 251.13M | 178.18M |
Cash Flow | |||||
Free Cash Flow | -70.32M | -55.42M | -29.65M | -113.02M | -25.66M |
Operating Cash Flow | -40.42M | -36.23M | -12.89M | -29.23M | -6.09M |
Investing Cash Flow | -18.17M | -12.04M | -16.10M | -106.80M | -19.68M |
Financing Cash Flow | 25.21M | 44.16M | ― | 180.69M | 103.77M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
58 Neutral | 676.19M | -7.18 | -25.23% | ― | 14.82% | -19.27% | |
54 Neutral | 1.26B | -8.53 | -38.32% | ― | 20.84% | 24.84% | |
51 Neutral | 255.13M | -0.86 | -36.15% | ― | 78.82% | -20.81% | |
50 Neutral | 1.98B | -12.02 | ― | ― | 60.04% | 52.49% | |
43 Neutral | 23.28M | -0.26 | -2271.61% | ― | -16.98% | 2.43% | |
41 Neutral | $198.91M | ― | -45.13% | ― | -14.27% | -28.56% | |
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% |
On September 1, 2025, NOVONIX Limited announced the issuance of 250,000 new ordinary fully paid securities on the Australian Securities Exchange (ASX) as a result of the conversion of performance rights. This move is part of the company’s strategy to enhance its capital structure and support its ongoing growth in the battery materials sector. The new securities are intended to rank equally with existing shares, reflecting NOVONIX’s commitment to expanding its market presence and providing value to its stakeholders.
On September 1, 2025, NOVONIX Limited announced the cessation of 3,236,775 performance rights due to the lapse of conditional rights that were not met. This development affects the company’s issued capital and reflects a strategic adjustment in its equity securities management, potentially impacting investor perceptions and market positioning.
On August 12, 2025, NOVONIX Ltd announced the issuance of 2,800,013 ordinary fully paid securities on the Australian Securities Exchange (ASX). This issuance resulted from the conversion of convertible debentures, reflecting the company’s strategic financial maneuvers to optimize its capital structure. The new securities are intended to be quoted on the ASX, aligning with NOVONIX’s ongoing efforts to enhance its market presence and shareholder value.
On August 1, 2025, NOVONIX Limited announced that it, along with Lithium Energy Limited, has decided not to proceed with the Initial Public Offering (IPO) of Axon Graphite due to unfavorable market conditions. This decision affects the planned spin-out of their consolidated graphite assets, initially intended to be completed under the Mt Dromedary Share Sale and Purchase Agreement. The company is now reassessing strategies to maximize shareholder value from the Mt Dromedary asset, and NOVONIX’s nominees have resigned from their director positions at Axon Graphite.
On July 29, 2025, NOVONIX Limited announced the issuance of 48,531 ordinary fully paid securities on the Australian Securities Exchange (ASX) as a result of the conversion of performance rights. This move is part of the company’s ongoing efforts to enhance its capital structure by converting existing securities into additional quoted securities, which could potentially improve liquidity and market perception.
On July 2, 2025, NOVONIX Ltd announced the issuance of 82,506 performance rights under an employee incentive scheme, which are not intended to be quoted on the ASX. This move is part of the company’s strategy to incentivize its workforce, potentially enhancing employee motivation and aligning their interests with the company’s growth objectives.
On June 30, 2025, NOVONIX Ltd announced the issuance of 66,896 ordinary fully paid securities on the Australian Securities Exchange (ASX) as a result of options being exercised and convertible securities being converted. This move is part of an employee incentive scheme, with some securities being converted by key management personnel. This development is expected to enhance the company’s operational capabilities and strengthen its market position in the battery materials industry.